Close Menu

financial guidance

Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.

The company said it achieved record volumes for its AlloMap non-invasive blood test for heart transplant patients.

After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.

The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.

The firm completed its acquisition of Nanosphere on June 30, and received FDA clearance and CE-IVD marking for the Aries M1 system on July 6.

The company said its organic revenue growth during the quarter was 4 percent, and that acquisitions increased revenue by 3 percent.

Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.

The company said it completed about 54,000 Cologuard tests in Q2, and that the cumulative number of physicians ordering the test since its launch has risen to 41,000.

Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.

Luminex's anticipated FY 2016 revenue growth of 6 percent to 9 percent could potentially push higher into the double digits following the integration of Nanosphere.

Pages

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.